التفاصيل البيبلوغرافية
| العنوان: |
Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in ‘real world’ patients with chronic hepatitis C. |
| المؤلفون: |
Gaeta, G. B., Precone, D. F., Felaco, F. M., Bruno, R., Spadaro, A., Stornaiuolo, G., Stanzione, M., Ascione, T., De Sena, R., Campanone, A., Filice, G., Piccinino, F. |
| المصدر: |
Alimentary Pharmacology & Therapeutics; Sep2002, Vol. 16 Issue 9, p1633-1639, 7p, 5 Charts |
| مصطلحات موضوعية: |
DRUG side effects, THERAPEUTIC use of interferons, HEPATITIS C treatment |
| مستخلص: |
SUMMARY Background : Interferon-α plus ribavirin therapy for chronic hepatitis C is associated with adverse effects that lead to therapy discontinuation in up to 27% of patients in randomized controlled trials. Aim : To examine the causes and predictive factors for therapy discontinuation in patients treated in current clinical practice. Methods : We retrospectively enrolled 441 consecutive patients, scheduled to receive interferon-α + ribavirin for chronic hepatitis C, in five centres. Patients had been treated with 3 or 6 MU interferon-α three times a week plus ribavirin, 800–1200 mg daily, for 6 or 12 months. Results : One hundred and eight [24.5%; confidence interval (CI), 20.5–28.8%] patients failed to finish combination therapy because of adverse events. The discontinuation rate was higher during the first 6 months of treatment; anaemia was an important cause (36.1% of discontinuations); unexplained lipothymia resulted in discontinuation in 11 patients. Female gender [hazard ratio (HR) = 1.85; CI, 1.17–2.92], an interferon-α dose > 15 MU/week (HR = 1.79; CI, 1.12–2.86) and no previous interferon-α treatment (HR = 1.63; CI, 1.04–2.57) were independent factors associated with discontinuation. The simultaneous presence of these factors identified patients at high risk for discontinuation [odds ratio (OR) = 10; CI, 3.98–25.13]. Conclusions : The study identified some predictive factorsfor adverse event-related discontinuation, which may improve the safety profile and effectiveness of interferon-α + ribavirin combination therapy in chronic hepatitis C. [ABSTRACT FROM AUTHOR] |
|
Copyright of Alimentary Pharmacology & Therapeutics is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder